Impact of Antiphospholipid Antibodies on COVID-19 Severity and Patient Outcomes
-
By
-
Batool Zamani
-
Maedeh Najafizadeh
-
Atiye Jokar
-
Habibollah Rahimi
-
Hossein Motedayyen
-
January 29, 2026
-
Clinical Scorecard: Impact of Antiphospholipid Antibodies on COVID-19 Severity and Patient Outcomes
At a Glance
| Category | Detail |
|---|
| Condition | |
| Key Mechanisms | Hypercoagulable state (increased blood clotting tendency) and cytokine storm (excessive immune response). |
| Target Population | |
| Care Setting | |
Key Highlights
- Antiphospholipid syndrome (APS) is linked to increased thrombotic events in COVID-19, with studies showing a X% increase in thrombotic complications.
- Severe COVID-19 cases often require hospitalization and mechanical ventilation, with Y% of patients progressing to severe disease.
- Presence of antiphospholipid antibodies may exacerbate COVID-19 severity, correlating with Z% higher risk of severe outcomes.
Guideline-Based Recommendations
Diagnosis
Management
- Administer subcutaneous heparin to prevent thrombotic complications.
- Consider additional anticoagulants based on patient risk factors.
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Patients were not on medications affecting immune responses at sampling; moderate cases defined by SpO₂ ≥ 94%.
Clinical Best Practices
- Utilize updated international classification criteria for APS diagnosis.
- Conduct thorough clinical assessments for COVID-19 severity.
- Include follow-up care recommendations for patients post-COVID-19.
References
